Bruce Goldsmith
Plus aucun poste en cours
Profil
Bruce A.
Goldsmith served as President, Chief Executive Officer & Director at Passage Bio, Inc. from 2021 to 2022.
He was also the Chief Executive Officer at Civetta Therapeutics LLC in 2019-2020.
Prior to that, he held senior positions at Allos Therapeutics, Inc., Lycera Corp., and GPC Biotech, Inc. He was a Venture Partner at Deerfield Management Co. LP in 2019-2020.
Dr. Goldsmith holds a doctorate from the University of Pennsylvania, an undergraduate degree from Colgate University, and an MBA from Columbia Business School.
Anciens postes connus de Bruce Goldsmith
| Sociétés | Poste | Fin |
|---|---|---|
| PASSAGE BIO, INC. | Chief Executive Officer | 31/05/2022 |
Civetta Therapeutics LLC
 Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Civetta Therapeutics LLC develops therapeutics for cancers and other diseases. The company was founded by William Sellers and Eric Fischer and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2020 |
Deerfield Management Co. LP
 Deerfield Management Co. LP Investment ManagersFinance Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles. | Corporate Officer/Principal | 01/01/2020 |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Chief Operating Officer | 01/01/2019 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 05/09/2012 |
Formation de Bruce Goldsmith
| University of Pennsylvania | Doctorate Degree |
| Colgate University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Deerfield Management Co. LP
Deerfield Management Co. LP Investment ManagersFinance Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles. | Finance |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Civetta Therapeutics LLC
Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Civetta Therapeutics LLC develops therapeutics for cancers and other diseases. The company was founded by William Sellers and Eric Fischer and is headquartered in Cambridge, MA. | Health Technology |
